Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
79 hedge funds and large institutions have $249M invested in Kinnate Biopharma Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 26 reducing their positions, and 13 closing their positions.
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
6% less funds holding
Funds holding: 84 → 79 (-5)
12% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 26
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
47% less capital invested
Capital invested by funds: $472M → $249M (-$224M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$2.64M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$561K |
| 3 |
BlackRock
New York
|
+$481K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$316K |
| 5 |
Squarepoint
New York
|
+$204K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$8.25M |
| 2 |
DM
Deerfield Management
New York
|
-$2.99M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.78M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$2.75M |
| 5 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$2.71M |
KNTE Hedge Fund Activity: Q4 2022 in Review
79 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q4 2022, worth a combined $249M — down 47% from $472M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of KNTE and 10 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 23 added.
The largest buyer was Lynx1 Capital Management, adding an estimated $2.64M. The largest seller was Boxer Capital, cutting an estimated $8.25M.
- 79 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q4 2022, down from 84 in Q3 2022.
- Funds reported $249M of Kinnate Biopharma Inc. Common Stock stock for Q4 2022, down 47% quarter-over-quarter.
- 10 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q4 2022 and 13 closed out, a net change of -3 holders.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q4 2022 was Lynx1 Capital Management, an estimated $2.64M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q4 2022 was Boxer Capital, an estimated $8.25M sold.
Based on aggregated 13F filings for Q4 2022.